Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Management of FL relapsed or progressed after frontline lenalidomide and rituximab

Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, discusses a retrospective study aiming to examine the treatment and outcome of follicular lymphoma (FL) patients who relapse and/or progress after an initial treatment with lenalidomide and rituximab (R2). Following relapse or progression, the patients received either chemoimmunotherapy or biological therapy. The median progression-free survival (PFS) was significantly longer in patients who received chemoimmunotherapy as compared to biological therapy at relapse. While these findings suggest that chemoimmunotherapy is an effective treatment strategy for patients with FL who relapse after frontline R2, the optimal salvage therapy for these patients needs to be further investigated. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.